Achaogen Stock Price, News & Analysis (NASDAQ:AKAO)

$11.10 0.49 (4.62 %)
(As of 12/11/2017 01:37 PM ET)
Previous Close$10.61
Today's Range$10.63 - $11.17
52-Week Range$5.08 - $27.79
Volume808,000 shs
Average Volume873,036 shs
Market Capitalization$470.57 million
P/E RatioN/A
Dividend YieldN/A
Beta1.36

About Achaogen (NASDAQ:AKAO)

Achaogen logoAchaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Receive AKAO News and Ratings via Email

Sign-up to receive the latest news and ratings for AKAO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKAO
CUSIPN/A
Phone650-800-3636

Debt

Debt-to-Equity Ratio0.08%
Current Ratio6.99%
Quick Ratio6.99%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$41.77 million
Price / Sales11.26
Cash FlowN/A
Price / CashN/A
Book Value$3.06 per share
Price / Book3.63

Profitability

Trailing EPS($3.60)
Net Income$-71,220,000.00
Net Margins-593.61%
Return on Equity-80.44%
Return on Assets-51.17%

Miscellaneous

Employees106
Outstanding Shares42,390,000

Achaogen (NASDAQ:AKAO) Frequently Asked Questions

What is Achaogen's stock symbol?

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

How were Achaogen's earnings last quarter?

Achaogen, Inc. (NASDAQ:AKAO) announced its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.13. The biopharmaceutical company had revenue of $0.58 million for the quarter, compared to analysts' expectations of $2.09 million. Achaogen had a negative net margin of 593.61% and a negative return on equity of 80.44%. The firm's quarterly revenue was down 96.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.41) earnings per share. View Achaogen's Earnings History.

Where is Achaogen's stock going? Where will Achaogen's stock price be in 2017?

9 Wall Street analysts have issued 12 month price objectives for Achaogen's stock. Their predictions range from $17.00 to $29.00. On average, they anticipate Achaogen's stock price to reach $25.63 in the next twelve months. View Analyst Ratings for Achaogen.

What are Wall Street analysts saying about Achaogen stock?

Here are some recent quotes from research analysts about Achaogen stock:

  • 1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (11/14/2017)
  • 2. Mizuho analysts commented, "We believe the recent price pullback from 52-week highs presents a buying opportunity especially considering Plazomicin represents meaningful advances in the aminoglycoside class with survival benefits ." (11/9/2017)
  • 3. Cowen Inc analysts commented, "We are assuming coverage of AKAO with an Outperform." (5/5/2017)
  • 4. Needham & Company LLC analysts commented, "Achaogen mgmt provided a 4Q16 corporate update yesterday. Company remains on track for plazomicin NDA submission 2H17. Details around manufacturing/ CMC were provided, including role for Pfizer McPherson facility in fill/ finish. An FDA Warning Letter was issued to Pfizer last month for matters unrelated to plazomicin at facility. We assume resolution is likely before PDUFA date in 2018. We await additional information on new oral beta-lactam/ BLI cUTI program (C-Scape), but believe commercial opportunity for oral drug in this indication is one of most attractive areas in antibiotic space." (3/15/2017)
  • 5. Aegis analysts commented, "Yesterday after market close, Achaogen announced fourth quarter results, reporting revenue of $10.7 mil vs. street consensus estimates of $12.4 mil and GAAP-EPS of $(1.04) vs. consensus of $(0.49). The EPS miss comes primarily from a $16.9 mil expense recorded in the fourth quarter related to changes in warrants and derivative liabilities that was associated with the capital raise completed in June, 2016. Achaogen is a clinical stage development company, as such we believe the financials are less important, milestones and catalysts tend to drive valuation for these types of companies." (3/15/2017)

Who are some of Achaogen's key competitors?

Who are Achaogen's key executives?

Achaogen's management team includes the folowing people:

  • Bryan E. Roberts Ph.D., Independent Chairman of the Board (Age 50)
  • Blake Wise, President, Chief Operating Officer (Age 46)
  • Kenneth J. Hillan, Chief Executive Officer, Director (Age 56)
  • Tobin Schilke, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer (Age 42)
  • Lee Swem Ph.D., Senior Vice President, Chief Scientific Officer (Age 41)
  • Zeryn Sarpangal, Senior Vice President - Corporate and People Strategy (Age 35)
  • Gary Loeb, General Counsel (Age 47)
  • Janet Dorling, Chief Commercial Officer
  • Karen Bernstein Ph.D., Independent Director
  • John C. Doyle, Independent Director (Age 48)

Who owns Achaogen stock?

Achaogen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (5.32%), TimesSquare Capital Management LLC (3.22%), Artal Group S.A. (0.59%), Candriam Luxembourg S.C.A. (0.43%), University of Notre Dame DU Lac (0.37%) and Bank of New York Mellon Corp (0.33%). Company insiders that own Achaogen stock include Blake Wise, Equity Opportunities Iv Growth, Gary Loeb, Ian Friedland, Kenneth J Hillan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen.

Who sold Achaogen stock? Who is selling Achaogen stock?

Achaogen's stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Iguana Healthcare Management LLC, Marcus Capital LLC, Candriam Luxembourg S.C.A., New York State Common Retirement Fund, TD Asset Management Inc. and Russell Investments Group Ltd.. Company insiders that have sold Achaogen company stock in the last year include Blake Wise, Gary Loeb, Ian Friedland, Kenneth J Hillan, Tobin Schilke and Zeryn Sarpangal. View Insider Buying and Selling for Achaogen.

Who bought Achaogen stock? Who is buying Achaogen stock?

Achaogen's stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., TimesSquare Capital Management LLC, Schwab Charles Investment Management Inc., University of Notre Dame DU Lac, Artal Group S.A., Hikari Power Ltd, First Midwest Bank Trust Division and Sei Investments Co.. View Insider Buying and Selling for Achaogen.

How do I buy Achaogen stock?

Shares of Achaogen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achaogen's stock price today?

One share of Achaogen stock can currently be purchased for approximately $11.10.

How big of a company is Achaogen?

Achaogen has a market capitalization of $470.57 million and generates $41.77 million in revenue each year. The biopharmaceutical company earns $-71,220,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. Achaogen employs 106 workers across the globe.

How can I contact Achaogen?

Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected]


MarketBeat Community Rating for Achaogen (AKAO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  349
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Achaogen (NASDAQ:AKAO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.902.902.902.88
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.89$23.89$26.00$25.43
Price Target Upside: 118.36% upside70.39% upside41.46% upside5.86% upside

Achaogen (NASDAQ:AKAO) Consensus Price Target History

Price Target History for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ:AKAO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/30/2017MizuhoReiterated RatingBuy$28.00HighView Rating Details
11/9/2017Stifel NicolausLower Price TargetBuy -> Buy$30.00 -> $27.00N/AView Rating Details
11/9/2017HC WainwrightReiterated RatingPositive -> Buy$25.00N/AView Rating Details
10/24/2017GuggenheimInitiated CoverageBuy$17.00N/AView Rating Details
10/9/2017Leerink SwannReiterated RatingOutperform -> Outperform$28.00 -> $22.00N/AView Rating Details
5/15/2017CowenReiterated RatingOutperformN/AView Rating Details
4/24/2017WedbushReiterated RatingOutperform$28.00HighView Rating Details
3/30/2017AegisDowngradeBuy -> Hold$29.00LowView Rating Details
3/15/2017Needham & Company LLCReiterated RatingBuy$29.00MediumView Rating Details
9/26/2016SunTrust BanksReiterated RatingBuy$10.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Achaogen (NASDAQ:AKAO) Earnings History and Estimates Chart

Earnings by Quarter for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ AKAO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3($0.72)($0.85)$2.09 million$0.58 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.60)($0.78)$2.69 million$1.30 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.54)($0.93)$3.81 million$7.46 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.49)($1.04)$13.33 million$10.73 millionViewN/AView Earnings Details
11/7/2016Q3($0.61)($0.41)$8.72 million$16.05 millionViewListenView Earnings Details
8/8/2016Q2($0.67)($0.87)$5.58 million$9.14 millionViewN/AView Earnings Details
3/15/2016Q414($0.58)($0.61)$5.33 million$4.70 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.46)($0.48)$5.10 million$4.48 millionViewN/AView Earnings Details
8/10/2015Q2 2015($0.20)($0.05)$8.65 million$12.04 millionViewN/AView Earnings Details
5/11/2015Q1 2015($0.25)($0.34)$5.00 million$4.88 millionViewN/AView Earnings Details
3/16/2015Q4 2014($0.33)($0.27)$4.96 million$4.26 millionViewN/AView Earnings Details
11/10/2014Q314($0.18)($0.47)$6.00 million$4.52 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.19)($0.20)$5.99 million$5.20 millionViewN/AView Earnings Details
5/12/2014Q114($0.21)($1.00)$5.39 million$6.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Achaogen (NASDAQ:AKAO) Earnings Estimates

2017 EPS Consensus Estimate: ($2.65)
2018 EPS Consensus Estimate: ($3.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.56)($0.48)($0.54)
Q2 20174($0.71)($0.58)($0.66)
Q3 20174($0.88)($0.62)($0.72)
Q4 20174($0.99)($0.59)($0.74)
Q1 20183($1.03)($0.63)($0.80)
Q2 20183($0.91)($0.69)($0.78)
Q3 20184($0.90)($0.70)($0.80)
Q4 20183($0.91)($0.61)($0.75)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Achaogen (NASDAQ:AKAO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Achaogen (NASDAQ AKAO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.36%
Institutional Ownership Percentage: 85.81%
Insider Trades by Quarter for Achaogen (NASDAQ:AKAO)
Institutional Ownership by Quarter for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ AKAO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/26/2017Blake WiseCOOSell3,576$15.99$57,180.24View SEC Filing  
9/26/2017Gary LoebGeneral CounselSell1,146$15.99$18,324.54View SEC Filing  
6/12/2017Tobin SchilkeCFOSell2,066$21.53$44,480.98View SEC Filing  
1/26/2017Gary LoebGeneral CounselSell521$16.78$8,742.38View SEC Filing  
1/26/2017Ian FriedlandInsiderSell695$16.78$11,662.10View SEC Filing  
1/26/2017Kenneth J. HillanCEOSell1,431$16.78$24,012.18View SEC Filing  
1/26/2017Tobin SchilkeCFOSell955$16.78$16,024.90View SEC Filing  
1/26/2017Zeryn SarpangalVPSell781$16.78$13,105.18View SEC Filing  
12/19/2016Equity Opportunities Iv GrowthMajor ShareholderBuy500,000$13.50$6,750,000.00View SEC Filing  
9/27/2016Blake WiseCOOSell3,632$4.30$15,617.60View SEC Filing  
9/27/2016Zeryn SarpangalVPSell1,069$4.30$4,596.70View SEC Filing  
3/17/2016Ian FriedlandInsiderSell1,772$3.22$5,705.84View SEC Filing  
3/17/2016Kenneth J HillanCEOSell3,572$3.22$11,501.84View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Achaogen (NASDAQ AKAO) News Headlines

Source:
DateHeadline
Achaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $1.78 MillionAchaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $1.78 Million
www.americanbankingnews.com - December 2 at 6:00 AM
Achaogen, Inc. (AKAO) Expected to Post Earnings of -$0.79 Per ShareAchaogen, Inc. (AKAO) Expected to Post Earnings of -$0.79 Per Share
www.americanbankingnews.com - November 30 at 9:32 PM
Achaogen (AKAO) Earns Buy Rating from MizuhoAchaogen (AKAO) Earns Buy Rating from Mizuho
www.americanbankingnews.com - November 30 at 4:42 PM
Achaogen to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference - GlobeNewswire (press release)Achaogen to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 30 at 11:49 AM
Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock? - NasdaqIs the Options Market Predicting a Spike in Achaogen (AKAO) Stock? - Nasdaq
www.nasdaq.com - November 27 at 3:21 PM
Achaogen, Inc. (AKAO) Receives Consensus Rating of "Buy" from BrokeragesAchaogen, Inc. (AKAO) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 23 at 10:10 AM
Investors Purchase Large Volume of Achaogen Put Options (AKAO)Investors Purchase Large Volume of Achaogen Put Options (AKAO)
www.americanbankingnews.com - November 23 at 1:34 AM
Achaogen, Inc. (AKAO) Cut to Sell at Zacks Investment ResearchAchaogen, Inc. (AKAO) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - November 14 at 8:28 PM
Achaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $990,000.00Achaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $990,000.00
www.americanbankingnews.com - November 14 at 9:58 AM
Research Analysts Set Expectations for Achaogen, Inc.s Q3 2018 Earnings (AKAO)Research Analysts Set Expectations for Achaogen, Inc.'s Q3 2018 Earnings (AKAO)
www.americanbankingnews.com - November 13 at 7:54 AM
Q4 2017 EPS Estimates for Achaogen, Inc. Cut by Analyst (AKAO)Q4 2017 EPS Estimates for Achaogen, Inc. Cut by Analyst (AKAO)
www.americanbankingnews.com - November 13 at 5:16 AM
William Blair Weighs in on Achaogen, Inc.s Q4 2017 Earnings (AKAO)William Blair Weighs in on Achaogen, Inc.'s Q4 2017 Earnings (AKAO)
www.americanbankingnews.com - November 13 at 5:16 AM
Achaogen, Inc. Forecasted to Post FY2020 Earnings of ($0.18) Per Share (AKAO)Achaogen, Inc. Forecasted to Post FY2020 Earnings of ($0.18) Per Share (AKAO)
www.americanbankingnews.com - November 10 at 7:46 PM
Achaogen, Inc. (AKAO) Issues  Earnings ResultsAchaogen, Inc. (AKAO) Issues Earnings Results
www.americanbankingnews.com - November 10 at 8:23 AM
Achaogen, Inc. (AKAO) Announces Quarterly  Earnings Results, Misses Expectations By $0.13 EPSAchaogen, Inc. (AKAO) Announces Quarterly Earnings Results, Misses Expectations By $0.13 EPS
www.americanbankingnews.com - November 9 at 2:27 PM
HC Wainwright Lowers Achaogen, Inc. (AKAO) Price Target to $25.00HC Wainwright Lowers Achaogen, Inc. (AKAO) Price Target to $25.00
www.americanbankingnews.com - November 9 at 7:58 AM
Achaogens (AKAO) CEO Kenneth Hillan on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaAchaogen's (AKAO) CEO Kenneth Hillan on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 9 at 4:04 AM
Achaogen to Present at the Stifel 2017 Healthcare Conference - GlobeNewswire (press release)Achaogen to Present at the Stifel 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 7 at 2:34 AM
Achaogen to Host Conference Call and Webcast of Third Quarter 2017 Financial Results on November 8,Achaogen to Host Conference Call and Webcast of Third Quarter 2017 Financial Results on November 8,
www.nasdaq.com - October 30 at 4:32 PM
Achaogen, Inc. (AKAO) Given Buy Rating at MizuhoAchaogen, Inc. (AKAO) Given Buy Rating at Mizuho
www.americanbankingnews.com - October 30 at 6:16 AM
Can Achaogen Turn It Around After A Long Slide? - Seeking AlphaCan Achaogen Turn It Around After A Long Slide? - Seeking Alpha
seekingalpha.com - October 27 at 5:48 PM
Achaogen (AKAO) Reports FDA Submission of Plazomicin New Drug Application - StreetInsider.comAchaogen (AKAO) Reports FDA Submission of Plazomicin New Drug Application - StreetInsider.com
www.streetinsider.com - October 26 at 11:09 AM
 Analysts Expect Achaogen, Inc. (AKAO) Will Post Quarterly Sales of $1.69 Million Analysts Expect Achaogen, Inc. (AKAO) Will Post Quarterly Sales of $1.69 Million
www.americanbankingnews.com - October 25 at 7:54 PM
FY2019 EPS Estimates for Achaogen, Inc. Lowered by Leerink Swann (AKAO)FY2019 EPS Estimates for Achaogen, Inc. Lowered by Leerink Swann (AKAO)
www.americanbankingnews.com - October 12 at 4:18 PM
Achaogen, Inc. to Post Q3 2017 Earnings of ($0.72) Per Share, William Blair Forecasts (AKAO)Achaogen, Inc. to Post Q3 2017 Earnings of ($0.72) Per Share, William Blair Forecasts (AKAO)
www.americanbankingnews.com - October 11 at 8:00 AM
Achaogen (AKAO) versus Its Peers Critical SurveyAchaogen (AKAO) versus Its Peers Critical Survey
www.americanbankingnews.com - October 10 at 4:28 AM
Achaogens (AKAO) Outperform Rating Reaffirmed at Leerink SwannAchaogen's (AKAO) Outperform Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - October 9 at 10:02 AM
Achaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $1.69 MillionAchaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $1.69 Million
www.americanbankingnews.com - October 6 at 8:04 AM
Achaogen (AKAO) versus Reata Pharmaceuticals (RETA) Financial ReviewAchaogen (AKAO) versus Reata Pharmaceuticals (RETA) Financial Review
www.americanbankingnews.com - October 4 at 2:54 PM
Achaogen, Inc. (AKAO) Given Consensus Rating of "Buy" by AnalystsAchaogen, Inc. (AKAO) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - October 4 at 6:52 AM
Contrasting Achaogen (AKAO) & The CompetitionContrasting Achaogen (AKAO) & The Competition
www.americanbankingnews.com - October 2 at 12:22 AM
Achaogen, Inc. (AKAO) Earns Buy Rating from MizuhoAchaogen, Inc. (AKAO) Earns Buy Rating from Mizuho
www.americanbankingnews.com - September 29 at 2:06 PM
Insider Selling: Achaogen, Inc. (AKAO) General Counsel Sells 1,146 Shares of StockInsider Selling: Achaogen, Inc. (AKAO) General Counsel Sells 1,146 Shares of Stock
www.americanbankingnews.com - September 28 at 8:12 PM
Insider Selling: Achaogen, Inc. (AKAO) COO Sells 3,576 Shares of StockInsider Selling: Achaogen, Inc. (AKAO) COO Sells 3,576 Shares of Stock
www.americanbankingnews.com - September 28 at 7:48 PM
Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017 - GlobeNewswire (press release)Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017 - GlobeNewswire (press release)
globenewswire.com - September 28 at 4:16 PM
Achaogen (AKAO) Secures Max $18M Contract from BARDA for Support Development of Orally-Administered ... - StreetInsider.comAchaogen (AKAO) Secures Max $18M Contract from BARDA for Support Development of Orally-Administered ... - StreetInsider.com
www.streetinsider.com - September 28 at 4:16 PM
Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017
www.nasdaq.com - September 27 at 8:11 PM
Achaogen Adds Liz Bhatt as Chief Business Officer - GlobeNewswire (press release)Achaogen Adds Liz Bhatt as Chief Business Officer - GlobeNewswire (press release)
globenewswire.com - September 20 at 3:36 PM
Achaogen (AKAO) Appoints Liz Bhatt as Chief Business Officer - StreetInsider.comAchaogen (AKAO) Appoints Liz Bhatt as Chief Business Officer - StreetInsider.com
www.streetinsider.com - September 18 at 9:05 PM
ETFs with exposure to Achaogen, Inc. : September 18, 2017ETFs with exposure to Achaogen, Inc. : September 18, 2017
finance.yahoo.com - September 18 at 9:05 PM
-$0.72 Earnings Per Share Expected for Achaogen, Inc. (AKAO) This Quarter-$0.72 Earnings Per Share Expected for Achaogen, Inc. (AKAO) This Quarter
www.americanbankingnews.com - September 15 at 8:44 PM
Achaogen, Inc. (AKAO) Given Average Recommendation of "Buy" by BrokeragesAchaogen, Inc. (AKAO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 9 at 6:26 AM
Achaogen, Inc. (AKAO) Now Covered by Analysts at MizuhoAchaogen, Inc. (AKAO) Now Covered by Analysts at Mizuho
www.americanbankingnews.com - September 6 at 5:18 PM
Achaogen, Inc. :AKAO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017Achaogen, Inc. :AKAO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
finance.yahoo.com - September 5 at 4:56 PM
Achaogen Announces New Employment Inducement Grants - GlobeNewswire (press release)Achaogen Announces New Employment Inducement Grants - GlobeNewswire (press release)
globenewswire.com - August 21 at 8:54 PM
Achaogen, Inc. (AKAO) Given Average Rating of "Buy" by BrokeragesAchaogen, Inc. (AKAO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 15 at 6:50 AM
Achaogen to Present at the Wedbush PacGrow Healthcare Conference - GlobeNewswire (press release)Achaogen to Present at the Wedbush PacGrow Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - August 8 at 8:42 PM
Achaogen to Present at the Wedbush PacGrow Healthcare ConferenceAchaogen to Present at the Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 8 at 8:42 PM
Stifel Nicolaus Reaffirms Buy Rating for Achaogen, Inc. (NASDAQ:AKAO)Stifel Nicolaus Reaffirms Buy Rating for Achaogen, Inc. (NASDAQ:AKAO)
www.americanbankingnews.com - August 5 at 11:34 AM
BIOVERATIV INC (BIVV) vs. Achaogen (NASDAQ:AKAO) Head-To-Head ReviewBIOVERATIV INC (BIVV) vs. Achaogen (NASDAQ:AKAO) Head-To-Head Review
www.americanbankingnews.com - August 5 at 8:30 AM

SEC Filings

Achaogen (NASDAQ:AKAO) SEC Filings

DateFilerForm TypeView
12/11/2017
7:51 AM
Achaogen (Issuer)
DUGGAN ROBERT W (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
View Filing
12/08/2017
8:07 PM
Achaogen (Subject)
DUGGAN ROBERT W (Filed by)
Form SC 13D/A
View Filing
12/04/2017
8:08 AM
Achaogen (Filer)
Form CT ORDER
View Filing

Social Media

Financials

Achaogen (NASDAQ:AKAO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Achaogen (NASDAQ AKAO) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.